Building on 15 years of successful research led by Florian Klein at the University of Cologne, Togontech was founded in May 2024 as a spin-off from the university.
The company aims to accelerate the discovery and development of monoclonal antibody-based solutions for the prevention, treatment, and cure of infectious diseases.
Togontech forms strategic partnerships to advance promising antibody therapies and offers specialized discovery and development services to biotechnology and pharmaceutical companies worldwide.